Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium inwardly-rectifying channel subfamily J member 14 (KCNJ14)
- Target
- KCNJ14
- Molecular classification
- Ion channel, Potassium channel, Inward rectifier potassium channel
01
Overview
KCNJ14 encodes Potassium inwardly-rectifying channel subfamily J member 14, an integral membrane protein forming an inward-rectifier potassium channel (Kir2.4) that allows potassium ions to enter cells more readily than they exit[1][3][6]. This channel plays a key role in controlling neuronal and motor neuron excitability and modulating membrane potential, with additional functions in heart rate and epithelial transport[1][7]. Dysregulation of KCNJ14 has been linked to the progression and prognosis of several cancers, and its expression is proposed as a biomarker for cancer patient stratification and monitoring[7]. While mechanistic understanding and therapeutic targeting are nascent, research supports its relevance to both cancer biology and neurological/cardiac physiology[7].
- Other names
- Kir2.4IRK4ATP-sensitive inward rectifier potassium channel 14Inward rectifier K(+) channel Kir2.4Potassium channel, inwardly rectifying subfamily J member 14Potassium voltage-gated channel subfamily J member 14
02
Mechanism of action
Potassium channel modulation affecting cell excitability (for agents modulating KCNJ channel activity in general, not KCNJ14 specifically)
03
Biological functions
Regulation of membrane potentialControl of neuronal excitabilityHeart rate modulationNeurotransmitter releaseEpithelial electrolyte transportImmunological regulation
04
Disease associations
CancerCardiovascular diseaseNeurological disorders (e.g., potential link to Kluver-Bucy syndrome, periodic paralysis)
05
Safety considerations
Potential risk of cardiac arrhythmias and neuronal excitability disturbance if modulatedLimited information; further research needed to clarify on-target toxicity[7]
06
Interacting drugs
null (no specific drugs directly targeting KCNJ14 are well-established in current literature; ion channel modulators may interact indirectly but without clinical specificity reported)
07
Biomarkers
KCNJ14 expression (prognostic biomarker for several cancers, including colorectal cancer and others)Genomic markers: associated with tumor mutation burden (TMB), microsatellite instability (MSI), neoantigen load, and PD-L1 expression in some cancers[7]
Beyond the preview
Go deeper on Potassium inwardly-rectifying channel subfamily J member 14 (KCNJ14).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Potassium inwardly-rectifying channel subfamily J member 14 (KCNJ14).